Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPECTA: Cabazitaxel with Prophylaxis in mCRPC
NCT01649635Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jul 2012
- Primary completion
- Jan 2014
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Started Jul 2012; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01649635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01649635.